Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

Journal of Clinical Oncology

Volumn 22, Issue 15, 2004, Pages 3133-3138

  Hoang Xuan, K ^a   Capelle, L ^a   Kujas, M ^a   Taillibert, S ^a   Duffau, H ^a   Lejeune, J ^a   Polivka, M ^a   Criniere E ^a   Marie, Y ^a   Mokhtari, K ^a   Carpentier, A F ^a   Laigle, F ^a   Simon, J M ^a   Cornu, P ^a   Broet P ^a   Sanson, M ^a   Delattre, J Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME LOSS; DISEASE COURSE; EPILEPSY; FEMALE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; AGED; BRAIN TUMOR; CHROMOSOME 1; GENETICS; HETEROZYGOSITY LOSS; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; DACARBAZINE; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OLIGODENDROGLIOMA;

EID: 4143143288     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.169     Document Type: Article

References (30)

1. Coons SW, Johnson PC, Scheithauer BW, et al: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393, 1997
2. Daumas-Duport C, Varlet P, Tucker M-L, et al: Oligodendrogliomas: Part 1-Patterns of growth, histological diagnosis, clinical and imaging correlations - A study of 153 cases. J Neurooncol 34:37-59, 1997
3. Giannini C, Scheitauer BW, Weaver AL, et al: Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248-262, 2001
4. Mandonnet E, Delattre JY, Tanguy ML, et al: Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53:524-528, 2003
5. Keles GE, Lamborn KR, Berger MS: Low grade hemispheric gliomas in adults: A critical review of extent of resection of low grade tumors. J Neurosurg 95:735-745, 2001
6. Karim AB, Maat B, Hatlevoll R, et al: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36:549-556, 1996
7. Karim AB, Afra D, Cornu P, et al: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4 - An interim analysis. Int J Radiat Oncol Biol Phys 52:316-324, 2002
8. Shaw E, Arussel R, Scheithauer B, et al: Prospective randomized trial of low versus high-dose radiation therapy in adults with supratentorial low grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267-2276, 2002
9. Olson JD, Riedel E, DeAngelis LM: Long term outcome of low grade oligodendroglioma and mixed glioma. Neurology 54:1442-1448, 2000
10. Benin A, Hoang-Xuan K, Carpentier A, et al: Primary brain tumours in adults. Lancet 361:323-331, 2003
11. Cairncross JG, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994
12. Van den Bent M, Kros JM, Heimans JJ, et al: Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy. Neurology 51:1140-1145, 1998
13. Paleologos NA, MacDonald DR, Vick NA, et al: Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53:1141-1143, 1999
14. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
15. Ino Y, Betensky RA, Zlatescu MC, et al: Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7:839-845, 2001
16. Buckner JC, Gesme D, O'Fallon JR, et al: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251-255, 2003
17. Chinot OL, Honore S, Dufour H, et al: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19:2449-2455, 2001
18. Van den bent MJ, Taphoorn MJB, Brandes AA, et al: Phase II study of first line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525-2528, 2003
19. Quinn JA, Reardon DA, Friedman AH, et al: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646-651, 2003
20. Pace A, Vidiri A, Galiè E, et al: Temozolomide chemotherapy for progressive low grade glioma: Clinical benefits and radiological response. Ann Oncol 14:1722-1726, 2003
21. Brada M, Viviers L, Abson C, et al: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II glioma. Ann Oncol 14:1715-1721, 2003
22. Hoang-Xuan K, He J, Huguet S, et al: Molecular heterogeneity of oligodendrogliomas suggest alternative pathways in tumoral progression. Neurology 57:1278-1281, 2001
23. Kleihues P, Cavenee WK: Pathology and Genetics: Tumours of the nervous system-WHO Classification of Tumours. Lyon, France, IARC Press, 2000
24. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 46:203-207, 1996
25. Soffietti R, Ruda R, Borgognone M, et al: Chemotherapy with PCV for low grade nonenhancing oligodendrogliomas and oligoastrocytomas. Neurology 52:423, 1999 (abstr POS-073, suppl 2)
26. Reifenberger J, Reifenberger G, Liu L, et al: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175-1190, 1994
27. Smith JS, Perry A, Borell TJ, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000
28. Van den Bent MJ, Looijenga LHJ, Langenberg K, et al: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284, 2003
29. Chahlavi A, Kanner A, Peereboom D, et al: Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: Preliminary results. J Neurooncol 61:267-273, 2003
30. Sasaki H, Zlatescu MC, Betensky RA, et al: Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma." J Neuropathol Exp Neurol 61:58-63, 2002